Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.36 USD
Change Today -0.016 / -4.21%
Volume 3.0M
RXII On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
NASDAQ CM
Frankfurt
As of 8:10 PM 05/29/15 All times are local (Market data is delayed by at least 15 minutes).

rxi pharmaceuticals (RXII) Snapshot

Open
$0.37
Previous Close
$0.38
Day High
$0.38
Day Low
$0.36
52 Week High
09/3/14 - $3.98
52 Week Low
05/28/15 - $0.34
Market Cap
22.6M
Average Volume 10 Days
2.0M
EPS TTM
$-0.67
Shares Outstanding
62.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RXI PHARMACEUTICALS (RXII)

Related News

No related news articles were found.

rxi pharmaceuticals (RXII) Related Businessweek News

No Related Businessweek News Found

rxi pharmaceuticals (RXII) Details

RXi Pharmaceuticals Corporation, a biotechnology company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and Samcyprone, an immunomodulation agent, which is in Phase IIa clinical trial for the treatment of various disorders, such as alopecia areata, warts, and cutaneous metastases of melanoma. The company’s preclinical program includes the development of products for ocular indications with RXI-109, including retinal and corneal scarring. Its discovery stage development programs include a dermatology franchise for the discovery of collagenase and tyrosinase targets for its RNAi platform; and ophthalmology franchise, a program for the discovery of sd-rxRNA compounds for oncology indications, including retinoblastoma. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

15 Employees
Last Reported Date: 05/22/15
Founded in 2011

rxi pharmaceuticals (RXII) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $495.3K
Chief Development Officer
Total Annual Compensation: $413.6K
Compensation as of Fiscal Year 2014.

rxi pharmaceuticals (RXII) Key Developments

RXi Pharmaceuticals Corporation Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2015

RXi Pharmaceuticals Corporation reported unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported total revenues of $34,000 against $29,000 a year ago. Loss from operations was $2,946,000 against $2,290,000 a year ago. Net loss was $2,945,000 against $2,284,000 a year ago. Net loss applicable to common stockholders was $3,130,000 against $4,039,000 a year ago. Basic and diluted loss per share was $0.13 against $0.32 a year ago. The decrease in net loss applicable to common stockholders for the quarter was primarily attributable to a decrease in the company's closing common stock price on the dividend payment dates and the number of preferred shares earning dividends each quarter.

RXi Pharmaceuticals Receives Non-Compliance Notice From Nasdaq

On May 7, 2015, RXi Pharmaceuticals Corporation received written notice from the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company’s common stock for the 30 consecutive business days prior to the date of the Notification Letter, the Company no longer meets the minimum bid price requirement. The Notification Letter does not impact the Company’s listing on The Nasdaq Capital Market at this time. The Notification Letter states that the Company has 180 calendar days, or until November 3, 2015, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the bid price of the Company’s common stock must have a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days at any time prior to November 3, 2015. In the event that the Company does not regain compliance by November 3, 2015, the Company may be eligible for additional time to reach compliance with the minimum bid price requirement.

RXi Pharmaceuticals Corporation to Report Q1, 2015 Results on May 13, 2015

RXi Pharmaceuticals Corporation announced that they will report Q1, 2015 results at 5:00 PM, Eastern Standard Time on May 13, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RXII:US $0.36 USD -0.016

RXII Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RXII.
View Industry Companies
 

Industry Analysis

RXII

Industry Average

Valuation RXII Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 113.8x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 45.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RXI PHARMACEUTICALS, please visit www.rxipharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.